Neuland Labs Q2 FY27: Revenue Falls 12.6%, Net Profit Declines 46.7% as Margins Contract
The company is an Indian pharmaceutical company engaged in manufacturing active pharmaceutical ingredients (APIs), complex intermediates and providing contract development and manufacturing services (CDMO/CMS). The company serves pharmaceutical customers across international markets, with capabilities in generic APIs, speciality molecules and complex chemistry.
The Nifty 50 is trading at 23,930.55, up by 0.55%, while the Sensex gained to 77,296.33, up by 0.49% on Wednesday. The shares of Neuland Labs are currently trading at Rs. 19,521.00, up by 0.50%. The company has a market capitalisation of Rs. 24,747.57 crore. The stock’s 52 week high is Rs. 24,225.00 and its 52 week low is Rs. 11,500.00. In the past 6 months, the stock has delivered a return of 21.16%.
What's the News?
Neuland Laboratories announced its consolidated financial results for the second quarter of FY27, reporting a 12.6% year-on-year decline in revenue from operations to Rs. 449.7 crore from Rs. 514.3 crore in Q2 FY26.
The company's operating performance also weakened during the quarter. EBITDA declined 37.3% to Rs. 97.6 crore from Rs. 155.6 crore in the corresponding quarter last year. EBITDA margin contracted to 21.7% from 30.2%, indicating pressure on operating profitability.
Net profit fell 46.7% year-on-year to Rs. 51.6 crore compared with Rs. 96.9 crore in Q2 FY26. The decline in earnings was sharper than the fall in revenue, reflecting the impact of lower operating margins.
Business Developments and Growth Outlook
Despite the weaker quarterly performance, Neuland continues to focus on expanding its contract manufacturing and specialty API businesses. Its commercial CMS projects remain an important growth driver, supported by new project orders and opportunities across its development pipeline.
The company has also inaugurated a new peptide manufacturing facility and acquired 134 acres of land in Kakinada for long-term capacity expansion. During Q2 FY27, it filed two Drug Master Files (DMFs) for Fezolinetant and Ivacaftor.
Management indicated that its growth expectations for FY27 and beyond remain intact, with commercial CMS molecules expected to support near-term growth. These developments could contribute to the company's business expansion over the coming years, although their financial contribution will depend on project execution and commercialisation.
Financial Performance
Looking at the quarterly results of Neuland Laboratories Limited, consolidated revenue from operations declined by 12.6% year-on-year to Rs. 449.7 crore in Q2 FY27 compared with Rs. 514.3 crore in Q2 FY26. On a sequential basis, revenue declined by 29.9% from Rs. 641.6 crore in Q1 FY27.
The company's consolidated EBITDA declined by 37.3% year-on-year to Rs. 97.6 crore from Rs. 155.6 crore, while EBITDA margin contracted to 21.7% from 30.2%. Consolidated net profit declined by 46.7% to Rs. 51.6 crore compared with Rs. 96.9 crore in the corresponding quarter last year. Sequentially, net profit fell by 65.0% from Rs. 147.7 crore in Q1 FY27.
Basic earnings per share (EPS) declined by 46.7% year-on-year to Rs. 40.24 in Q2 FY27 from Rs. 75.49 in Q2 FY26. Compared with Rs. 115.10 in the previous quarter, EPS declined by 65.0%.
For the first half of FY27, Neuland Laboratories reported consolidated revenue from operations of Rs. 1,091.2 crore compared with Rs. 807.0 crore in H1 FY26, registering growth of approximately 35.2%.
Consolidated net profit for the first half stood at Rs. 199.3 crore compared with Rs. 110.3 crore in the corresponding period last year, reflecting strong year-on-year growth despite the weaker Q2 performance. This indicates that the company's first-half performance remained higher than the previous year, supported by its stronger results in the earlier quarter.
Investor Perspective
Neuland Laboratories' Q2 FY27 results highlight the pressure on its operating performance, with revenue, EBITDA and net profit all declining compared with the year-ago quarter. The contraction in EBITDA margin also indicates that profitability remains an important area to monitor.
However, the company's H1 FY27 growth, expanding CMS pipeline and investments in peptide manufacturing and future capacity provide important context to its longer-term business outlook. Investors may track the execution of new projects, commercialisation of development-stage molecules and recovery in operating margins in the coming quarters.